Yarrow Bioscience, Inc. (YARW) stock
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)
Close on Nov 17, 2026Market cap $37.94MP/E –Yield –
Yarrow Bioscience ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Yarrow Bioscience's ebitda for the twelve months ending Jun 30, 2024 was -$30.84M. For fiscal 2025 it was -$29.73M. The highest annual figure on record is -$29.26M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$29.73M | – |
| FY2024 | Dec 31, 2024 | -$43.63M | – |
| FY2023 | Dec 31, 2023 | -$29.26M | – |
| FY2022 | Dec 31, 2022 | -$34.22M | – |
| FY2021 | Dec 31, 2021 | -$38.80M | – |
| FY2020 | Dec 31, 2020 | -$252.21M | – |
| FY2019 | Dec 31, 2019 | -$95.52M | – |
| FY2018 | Dec 31, 2018 | -$74.57M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.81M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.40M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.16M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.28M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.65M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.82M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.51M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.90M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.42M | – |
| Q2 FY2020 | Jun 30, 2020 | -$167.08M | – |
| Q1 FY2020 | Mar 31, 2020 | -$39.80M | – |
| Q4 FY2019 | Dec 31, 2019 | -$37.34M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.27M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.81M | – |
See a number that looks wrong?